FOR IMMEDIATE RELEASE
Contact: Sara Hinkley (713) 240-0143

THE CHOLANGIOCARCINOMA FOUNDATION SPONSORS
CONQUER CANCER FOUNDATION OF ASCO YOUNG
INVESTIGATOR AWARD

Salt Lake City, UT - The Cholangiocarcinoma Foundation has announced it is supporting the 2011 Conquer Cancer Foundation of ASCO Young Investigator Award in Cholangiocarcinoma Research. The one-year, $50,000 grant will be given to a promising investigator conducting research in cholangiocarcinoma (bile duct cancer). Awarded by the Conquer Cancer Foundation of the American Society of Clinical Oncology (formerly known as The ASCO Cancer Foundation), the grant is intended to raise awareness and trigger progress against this rare disease, while providing critical funding for physician-scientists at the beginning of their careers.

“The Cholangiocarcinoma Foundation analyzed the successes and failures of other organizations in funding research, and found that many successful programs funded researchers early in their investigative careers,” says President Sara Hinkley. She added, “Providing early-career grants helps encourage investigators to focus their careers on cholangiocarcinoma. While the Foundation has strong relationships with leading hepatobiliary cancer researchers, building a quality grant-review program is challenging and requires dedicated resources currently not available.”

The Conquer Cancer Foundation Grants Selection Committee will determine the recipient by evaluating the scientific merit and potential career-development impact of the Young Investigator Award applications using a two-part peer-review process. Grant recipients will be announced in April 2011.

For more information or to donate in support of the Young Investigator Award in Cholangiocarcinoma Research, please contact the Cholangiocarcinoma Foundation at (801) 999-0455 or visit us on the web at www.cholangiocarcinoma.org. To learn more about the Conquer Cancer Foundation, visit www.ConquerCancerFoundation.org.

The Cholangiocarcinoma Foundation is a 501 (c) (3) non-profit organization. Its vision is to bring a CURE for cholangiocarcinoma through increasing the Collaboration, Understanding, Research and Education of bile duct cancer.

###